Researchers published an integrated platform that combines targeted epigenetic edits with multiplexed genetic engineering to reprogram primary human T cells, reporting enhanced functional profiles for adoptive cell therapy in Nature Biotechnology. The work demonstrates simultaneous modulation of multiple gene programs in primary T cells without extensive genomic disruption. The study, authored by teams including the Arc Institute, Gladstone Institutes and UCSF and released online Oct. 21, details methods for stable, heritable transcriptional reprogramming alongside conventional CRISPR edits. The approach enables one‑step generation of multi‑feature T cells—an advance for off‑the‑shelf and engineered autologous therapies. For clinicians and developers, the paper provides technical benchmarks for multiplex editing in manufacturing‑relevant cell populations and highlights safety readouts used to assess epigenetic perturbations. The method’s compatibility with primary human material suggests near‑term translational experiments and candidate optimisation paths for next‑generation CAR‑T and T‑cell receptor (TCR) platforms.